PLSE - מכפיל PEG pulsebiosciences.com
Pulse Biosciences, Inc. (PLSE) is currently in the pre-commercial stage, where success depends on FDA approval and R&D expenditures. The PEG ratio reflects the market's valuation of the startup's prospects, with 0.00 representing the current metric. Innovations in non-thermal cell ablation allow the company to bypass traditional lasers, while the precise destruction of tumors without damaging blood vessels paves the way into cardiology.
Pulse Biosciences, Inc. (PLSE) - פילוחי מדדים ודוחות פיננסיים
The metric is calculated as the ratio of the P/E coefficient to the earnings growth rate, allowing for the determination of an asset's fair value based on its dynamics. In the context of Pulse Biosciences, Inc. (PLSE), this growth-based undervaluation assessment compares the market price with the commercialization potential of the CellFX technology and the launch of new electrodes, revealing the business's hidden margin of safety.
